Cite
HARVARD Citation
Blake, J. et al. (n.d.). The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers. European journal of cancer. pp. S144-S145. [Online].